N/A N=15 Diagnostic

Fluciclovine-PET/CT for Bone Metastases From Prostate Adenocarcinoma

Prostate Adenocarcinoma

Bottom Line

View on ClinicalTrials.gov: NCT03496844 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Aug 2022

Primary outcome: Primary: True Positive and False Positive Rates of F-18 Fluciclovine-PET/CT Findings Compared to Bone Biopsy — 13; 7; 6 participants

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: F-18 fluciclovine-PET/CT scan (Diagnostic_test)
Age: Adult, Older Adult · 18+ yrs
Sex: Male
Sponsor: University of Arizona
Primary completion: Apr 2021

Outcome Measures

Outcome	Result	p-value
PRIMARY True Positive and False Positive Rates of F-18 Fluciclovine-PET/CT Findings Compared to Bone Biopsy	13; 7; 6	—

Summary

Determine diagnostic accuracy of Axumin-PET positive bone lesion by confirmatory bone biopsy.

Eligibility Criteria

Inclusion Criteria

Male
Be ≥ 18 years of age
Diagnosed with prostate cancer
Be willing and able to provide informed consent
Be informed of the investigational nature of this study

Exclusion Criteria

Having a history of severe claustrophobia
Weight exceeding 400lbs

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03496844). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.